Convergent cross-species pro-cognitive effects of RGH-235, a new potent and selective histamine H 3 receptor antagonist/inverse agonist.

Autor: Némethy Z; Pharmacological and Drug Safety Research, Gedeon Richter Plc., Budapest, Hungary. Electronic address: nemethy@richter.hu., Kiss B; Pharmacological and Drug Safety Research, Gedeon Richter Plc., Budapest, Hungary., Lethbridge N; Department of Biosciences, Durham University, Durham, UK., Chazot P; Department of Biosciences, Durham University, Durham, UK., Hajnik T; Department of Physiology and Neurobiology, Eötvös Loránd University, Budapest, Hungary., Tóth A; Department of Physiology and Neurobiology, Eötvös Loránd University, Budapest, Hungary., Détári L; Department of Physiology and Neurobiology, Eötvös Loránd University, Budapest, Hungary., Schmidt É; Pharmacological and Drug Safety Research, Gedeon Richter Plc., Budapest, Hungary., Czurkó A; Pharmacological and Drug Safety Research, Gedeon Richter Plc., Budapest, Hungary., Kostyalik D; Pharmacological and Drug Safety Research, Gedeon Richter Plc., Budapest, Hungary., Oláh V; Department of Experimental Zoology and Neurobiology, Faculty of Sciences, Grastyán Translational Research Center and Szentágothai Research Center, University of Pécs, Pécs, Hungary., Hernádi I; Department of Experimental Zoology and Neurobiology, Faculty of Sciences, Grastyán Translational Research Center and Szentágothai Research Center, University of Pécs, Pécs, Hungary., Balázs O; Pharmacological and Drug Safety Research, Gedeon Richter Plc., Budapest, Hungary., Vizi ES; Institute of Experimental Medicine, Budapest, Hungary., Ledneczki I; Department of Chemistry, Gedeon Richter Plc., Budapest, Hungary., Mahó S; Department of Chemistry, Gedeon Richter Plc., Budapest, Hungary., Román V; Pharmacological and Drug Safety Research, Gedeon Richter Plc., Budapest, Hungary., Lendvai B; Pharmacological and Drug Safety Research, Gedeon Richter Plc., Budapest, Hungary., Lévay G; Pharmacological and Drug Safety Research, Gedeon Richter Plc., Budapest, Hungary.
Jazyk: angličtina
Zdroj: European journal of pharmacology [Eur J Pharmacol] 2022 Feb 05; Vol. 916, pp. 174621. Date of Electronic Publication: 2021 Dec 26.
DOI: 10.1016/j.ejphar.2021.174621
Abstrakt: The histamine H 3 receptor is a favourable target for the treatment of cognitive deficits. Here we report the in vitro and in vivo profile of RGH-235, a new potent, selective, and orally active H 3 receptor antagonist/inverse agonist developed by Gedeon Richter Plc. Radioligand binding and functional assays were used for in vitro profiling. Procognitive efficacy was investigated in rodent cognitive tests, in models of attention deficit hyperactive disorder (ADHD) and in cognitive tests of high translational value (rat touch screen visual discrimination test, primate fixed-foreperiod visual reaction time task). Results were supported by pharmacokinetic studies, neurotransmitter release, sleep EEG and dipsogenia. RGH-235 displayed high affinity to H 3 receptors (K i  = 3.0-9.2 nM, depending on species), without affinity to H 1 , H 2 or H 4 receptors and >100 other targets. RGH-235 was an inverse agonist ([ 35 S] GTPγS binding) and antagonist (pERK1/2 ELISA), showing favourable kinetics, inhibition of the imetit-induced dipsogenia and moderate effects on sleep-wake EEG. RGH-235 stimulated neurotransmitter release both in vitro and in vivo. RGH-235 was active in spontaneously hypertensive rats (SHR), generally considered as a model of ADHD, and revealed a robust pro-cognitive profile both in rodent and primate tests (in 0.3-1 mg/kg) and in models of high translational value (e.g. in a rodent touch screen test and in non-human primates). The multiple and convergent procognitive effects of RGH-235 support the view that beneficial cognitive effects can be linked to antagonism/inverse agonism of H 3 receptors.
(Copyright © 2021. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: